The rising trend of sweet-smelling gourmand fragrances coincides with anecdotal reports from GLP-1 weight-loss drug users ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Still, while Ozempic and Wegovy have secured ... led to the shakeup in company leadership. “The changes are made in light of the recent market challenges Novo Nordisk has been facing, and ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...

Despite leadership changes, the company maintains its strategy. Ready to turn the market’s comeback into ... Also Read: Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 ...